Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amikacin Sulfate

FDA-approved product (injectable, injection), marketed as Amikacin Sulfate, Amikacin Sulfate In Sodium Chloride 0.9% In Plastic Container, Amikin and 2 more.

Registered studies
50+
Lab records
133
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Amikacin Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Eye infection
  • Infection
  • Infectious meningitis
  • Lung disease
  • Peritonitis
  • Respiratory tract infectious disorder
  • Sepsis
  • Staphylococcus aureus infection
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antibiotics for topical use; Other aminoglycosides; Antibiotics
FDA pharmacologic class
Aminoglycoside Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01GB06; WHO ATC D06AX12; WHO ATC S01AA21; FDA class Aminoglycoside Antibacterial

Repurposing investigation

Amikacin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae84.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis88.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
  • E. coli: measured active in 6 of 8 lab records
  • K. pneumoniae: measured active in 73 of 115 lab records
  • M. tuberculosis: measured active in 9 of 9 lab records
Open Amikacin Sulfate in ChEMBL Registered studies below
Show the 133 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amikacin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Patients.

    NCT04470973 · start 2020-07-15

    Registered record
    Registry ID
    NCT04470973
    Conditions
    Sepsis; Septic Shock; Infection, Bacterial; Critically Ill
    Interventions
    Cefuroxime; Amikacin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-07-15
    Completion
    2023-12-15
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis; Septic Shock; Infection, Bacterial; Critically Ill
    InterventionCefuroxime; Amikacin
    PhaseNot recorded
    Registry statusUnknown

  • Prescription Strategies of Amikacin in Intensive Care Patients on Renal Replacement Therapy: an Observational Prospective Multicenter Study

    NCT04322019 · start 2020-05-25

    Registered record
    Registry ID
    NCT04322019
    Conditions
    Amikacin Treatment
    Interventions
    Data record
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-05-25
    Completion
    2022-05-16
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmikacin Treatment
    InterventionData record
    PhaseNot recorded
    Registry statusCompleted

  • Endophthalmitis Post Intravitreal Injections

    NCT04035369 · start 2020-03-01

    Registered record
    Registry ID
    NCT04035369
    Conditions
    Endophthalmitis
    Interventions
    Tap and Inject (TAI); Pars Plana Vitrectomy (PPV)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2020-03-01
    Completion
    2024-07
    Enrolment
    310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndophthalmitis
    InterventionTap and Inject (TAI); Pars Plana Vitrectomy (PPV)
    PhaseNot applicable
    Registry statusUnknown

  • Liposomal Amikacin Inhalation in M.Abscessus Patients

    NCT04163601 · start 2019-11-30

    Registered record
    Registry ID
    NCT04163601
    Conditions
    M.Abscessus Pulmonary Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-11-30
    Completion
    2024-03-31
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionM.Abscessus Pulmonary Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock

    NCT04178148 · start 2019-11-25

    Registered record
    Registry ID
    NCT04178148
    Conditions
    Shock, Septic
    Interventions
    Amikacin dose optimization
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2019-11-25
    Completion
    2022-12-02
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionShock, Septic
    InterventionAmikacin dose optimization
    PhaseNot applicable
    Registry statusCompleted

  • The Effect of 18-month Regimen Containing 6 Anti-tuberculosis Drugs for Patients With MDR-TB

    NCT03830671 · start 2019-03-08

    Registered record
    Registry ID
    NCT03830671
    Conditions
    Multi-drug Resistant Tuberculosis
    Interventions
    18-month regimen containing 6 anti-TB drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-03-08
    Completion
    2022-06-08
    Enrolment
    515

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMulti-drug Resistant Tuberculosis
    Intervention18-month regimen containing 6 anti-TB drugs
    PhasePhase 4
    Registry statusCompleted

  • Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children

    NCT03825874 · start 2019-01-19

    Registered record
    Registry ID
    NCT03825874
    Conditions
    Urinary Tract Infections; Urinary Tract Infections in Children
    Interventions
    Amikacin; usual antibiotic treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2019-01-19
    Completion
    2026-07
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections; Urinary Tract Infections in Children
    InterventionAmikacin; usual antibiotic treatment
    PhaseNot recorded
    Registry statusRecruiting

  • Use of Aaerosol Combined With Intravenous Antibiotics for the Treatment of Multidrug Resistant GNB Pneumonia

    NCT03921645 · start 2018-01-01

    Registered record
    Registry ID
    NCT03921645
    Conditions
    Ventilator Associated Pneumonia; Multi-antibiotic Resistance
    Interventions
    aerosol antibiotics
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-01-01
    Completion
    2020-01-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia; Multi-antibiotic Resistance
    Interventionaerosol antibiotics
    PhaseNot applicable
    Registry statusUnknown

  • Raja Isteri Pengiran Anak Saleha Appendicitis Treatment Without Operation

    NCT03169114 · start 2017-11-01

    Registered record
    Registry ID
    NCT03169114
    Conditions
    Appendicitis; Surgery
    Interventions
    Amikacin Injection; Appendicectomy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2017-11-01
    Completion
    2020-06-30
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAppendicitis; Surgery
    InterventionAmikacin Injection; Appendicectomy
    PhaseNot applicable
    Registry statusTerminated

  • BetaLACTA® Test for Early De-escalation of Empirical Carbapenems in Pulmonary, Urinary and Bloodstream Infections in ICU

    NCT03147807 · start 2017-10-20

    Registered record
    Registry ID
    NCT03147807
    Conditions
    Pneumonia; Urinary Tract Infections; Bloodstream Infection
    Interventions
    betaLACTA® rapid diagnostic test
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-10-20
    Completion
    2019-10-20
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia; Urinary Tract Infections; Bloodstream Infection
    InterventionbetaLACTA® rapid diagnostic test
    PhaseNot applicable
    Registry statusCompleted

  • Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212

    NCT02628600 · start 2016-02-05

    Registered record
    Registry ID
    NCT02628600
    Conditions
    NTM Lung Infection Due to MAC
    Interventions
    LAI 590 mg; Multi-drug regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-02-05
    Completion
    2018-10-17
    Enrolment
    163

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNTM Lung Infection Due to MAC
    InterventionLAI 590 mg; Multi-drug regimen
    PhasePhase 3
    Registry statusCompleted

  • The Effect of Colistin Inhalation on Ventilator Associated Pneumonia

    NCT03622450 · start 2016-01-02

    Registered record
    Registry ID
    NCT03622450
    Conditions
    Ventilator Associated Pneumonia
    Interventions
    Colistin; Carbapenem + Aminoglycoside/ Quinolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2016-01-02
    Completion
    2018-01-10
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia
    InterventionColistin; Carbapenem + Aminoglycoside/ Quinolone
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Comparison of Amikacin Lung Delivery With Two Nebulizers

    NCT02538588 · start 2015-08

    Registered record
    Registry ID
    NCT02538588
    Conditions
    Healthy; Cystic Fibrosis
    Interventions
    Nebulizer 1; Nebulizer 2
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2015-08
    Completion
    2015-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy; Cystic Fibrosis
    InterventionNebulizer 1; Nebulizer 2
    PhaseNot applicable
    Registry statusUnknown

  • Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone

    NCT02344004 · start 2015-05-27

    Registered record
    Registry ID
    NCT02344004
    Conditions
    Mycobacterium Infections, Nontuberculous
    Interventions
    LAI (Liposomal Amikacin for Inhalation) 590 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-05-27
    Completion
    2019-04-03
    Enrolment
    336

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Infections, Nontuberculous
    InterventionLAI (Liposomal Amikacin for Inhalation) 590 mg
    PhasePhase 3
    Registry statusCompleted

  • Impact of 30 mg/kg Amikacin and 8 mg/kg Gentamicin on Serum Concentrations in Critically Ill Patients With Severe Sepsis

    NCT02898961 · start 2014-10

    Registered record
    Registry ID
    NCT02898961
    Conditions
    Sepsis
    Interventions
    30 mg/kg amikacin or 8 mg/kg gentamicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-10
    Completion
    2016-12-31
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSepsis
    Intervention30 mg/kg amikacin or 8 mg/kg gentamicin
    PhasePhase 4
    Registry statusCompleted